Since the World Health Organization declared it a pandemic in March 2020, the novel coronavirus SARS-CoV-2 has caused millions of infections and hundreds of thousands of deaths worldwide. Currently there is no cure, and many initial treatments being tested against COVID-19 were designed for other viral infections. Multiple drugmakers are scrambling to find treatments that might help fight off the coronavirus or prevent infections altogether—in a Herculean effort to collapse the typical 10–15-year drug development timeline to under a year.
Antiviral human monoclonal antibodies (mAbs) are promising drug candidates for preventing or treating severe viral diseases, but the long timelines—on the order of years—needed for antibody discovery, functional analysis, preclinical studies, and manufacturing limit their rapid deployment and use as immunotherapeutics. Vanderbilt University Medical Center researchers Robert Carnahan and Pavlo Gilchuk are part of the scientific team attempting to compress the timeline for potent antiviral antibody discovery and characterization by integrating a series of advances in single-cell messenger RNA sequence analysis, bioinformatics, synthetic biology, and high-throughput functional analysis. Their work enabled the rapid discovery of a diverse panel of highly potent antiviral human mAbs against the SARS-CoV-2 Spike protein and the validation of their activity both in vitro and in vivo. These results provide a potential framework for expedited antibody discovery programs against viral pathogens of global concern.
During the webinar, viewers will:
- Hear about the integration of technological advances in high-throughput, single-cell analysis to enable rapid discovery of potent human mAbs
- Discover a streamlined approach to antiviral mAb discovery and therapeutic potency verification
- Learn how the development and use of mAbs as alternative antiviral therapeutics compares with conventional antiviral countermeasures, such as vaccines or small-molecule drugs
- Have the opportunity to ask questions during the live broadcast.
This webinar will last for approximately 60 minutes.
For Research Use Only. Not for use in diagnostic procedures.